Statement: PCORI Executive Director Joe Selby on the National Pharmaceutical Council's Fifth Annual Comparative Effectiveness Research Survey
- Our Programs
- Our Vision & Mission
- PCORI's New Strategic Plan
- Financials and Reports
- Evaluating Our Work
- Executive Team
- Office of the Executive Director
- Program Support and Information Management
- Staff Conflict of Interest Disclosures
- PCORI's Advisory Panels
- Procurement Opportunities
Past Opportunities to Provide Input
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
- Past Opportunities to Provide Input
- PCORI News Hub
PCORI Executive Director Joe Selby, MD, MPH, issued the following statement about today's release of the National Pharmaceutical Council’s fifth annual comparative effectiveness research survey.
“With more than 90 percent of respondents agreeing that comparative effectiveness research (CER) is important for our nation’s healthcare, the National Pharmaceutical Council’s fifth annual CER survey reaffirms the need for evidence that helps patients and those who care for them make better informed decisions.
“We’re pleased that those surveyed identified PCORI as the clear leader in setting CER priorities, establishing research standards, and funding studies.
“We believe this reflects the significant progress PCORI has made over a short time to produce and implement strong methodology standards and fund more than $700 million to support CER addressing a range of priority areas.
All of our initiatives – including our pragmatic clinical studies initiative and our efforts to build PCORnet, a national patient-centered clinical data research network – aim to generate real-world evidence about what works best for which patients. We’ll begin to see the first results of the CER studies we’ve funded later this year. We look forward to working with our many partners to disseminate and implement the results.
“We’re grateful to the National Pharmaceutical Council for its work to assess the impact of CER. This survey provides an opportunity to reflect on our collective progress and the work ahead to answer through CER the questions that matter most to patients, their caregivers, and healthcare providers.”
The Patient-Centered Outcomes Research Institute (PCORI) is an independent, non-profit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work.
- News Release